Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma

BACKGROUND: We performed a clinical trial to evaluate safety and immunogenicity of a novel long peptide vaccine administered in combinations of incomplete Freund’s adjuvant (IFA) and agonists for TLR3 (polyICLC) and TLR7/8 (resiquimod). We hypothesized that T cell responses to minimal epitope peptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Sapna P, Petroni, Gina R, Roszik, Jason, Olson, Walter C, Wages, Nolan A, Chianese-Bullock, Kimberly A, Smolkin, Mark, Varhegyi, Nikole, Gaughan, Elizabeth, Smith, Kelly T, Haden, Kathleen, Hall, Emily H, Gnjatic, Sacha, Hwu, Patrick, Slingluff, Craig L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378357/
https://www.ncbi.nlm.nih.gov/pubmed/34413169
http://dx.doi.org/10.1136/jitc-2021-003220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378357/
https://www.ncbi.nlm.nih.gov/pubmed/34413169
http://dx.doi.org/10.1136/jitc-2021-003220

Ejemplares similares